BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Yesterday 12:13 PM
China’s Food and Beverage Industry in Search of Methods to Shrink its Carbon Footprints
360 DigiTech: A Leader in an Oscillating Market
Updated 6 hours ago